Non-alcoholic Fatty Liver Disease
Conditions
Keywords
Jing-Si Herbal Tea
Brief summary
The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients
Detailed description
This study adopted a randomized double-blind design, 2-arm trial study. All eligible patients included in the study agreed to participated and signed the informed consent from and the study procedures were approved by the ethical committee of Taichung Tzu Chi general hospital (REC110-74). Patients were recruited from the Gastroenterology department of Taichung Tzu Chi hospital. After random assignment to 2 groups, patients will receive Jing-Si Herbal Tea or placebo twice a day for 24 weeks. We will evaluate the blood test results, abdominal ultrasound and physical examination every 12 weeks.
Interventions
OTHERJing-Si Herbal Tea
patient will receive twice in a day for 24 weeks
OTHERPlacebo Jing-Si Herbal Tea
Placebo Jing-Si Herbal Tea
Sponsors
Taichung Tzu Chi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Sign the Informed consent * Age between 20-70 * Diagnosis for moderated NAFLD * Liver disease without hepatic decompensation * HbA1c \< = 8.0 %
Exclusion criteria
* Do not sign the Informed consent * Other related liver diseases will affect the study which evaluated by physicians * Women of potential pregnancy or pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessing the changes from baseline blood glucose at 24 week | 24 week | Collect the data of blood glucose from blood test |
| Assessing the changes from baseline GOT (Glutamic Oxaloacetic Transaminase) at 24 week | 24 week | Collect the data of GOT from blood test |
| Assessing the changes from baseline GPT (Glutamic Pyruvic Transaminase) at 24 week | 24 week | Collect the data of GPT from blood test |
| Assessing the changes from baseline total cholesterol at 24 week | 24 week | Collect the data of total cholesterol from blood test |
| Assessing the changes from baseline triglycerides at 24 week | 24 week | Collect the data of triglycerides from blood test |
| Assessing the changes from baseline HDL-C at 24 week | 24 week | Collect the data of HDL-C from blood test |
| Assessing the changes from baseline LDL-C at 24 week | 24 weekk | Collect the data of LDL-C from blood test |
| Assessing the changes from baseline NAFLD activity at 24 week | 24 week | Scoring the level of NAFLD activity |
| Assessing the changes from baseline BMI at 24 week | 24 week | Collect the body height and body weight, weight and height will be combined to report BMI in kg/m\^2 |
Countries
Taiwan
Outcome results
None listed